Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), and anemia (29%). Twenty percent (20%) of patients experienced at least 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com.

This pre
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... California , 17 de septiembre de ... ("la compañía"), principal proveedor mundial de soluciones ... las ciencias de la vida, anunció hoy ... de logística global con sede en Rótterdam, ... base de clientes Europa en rápido crecimiento. ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... September 17, 2014 The ... , a multi-stakeholder non-profit collaborative building a global ... clinical research, today announced Phase 3 of its ... , Amir H. Kalali, Vice-President, Global Head, ... Bajpai, President, Compliance and Quality Integration (CQI) Consulting ...
(Date:9/16/2014)... jaw movements has been created by a group of ... device can generate electricity from eating, chewing and talking, ... electronic devices, such as hearing aids, cochlear implants, electronic ... of the device,s performance have been published today, 17 ... Structures . , Jaw movements have proved to be ...
Breaking Biology Technology:Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2
... Dec. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... and,medical device company, is scheduled to participate in ... December 12-13 in New York, NY., Tom ... in a panel discussion on Thursday, December 13, ...
... Raven,biotechnologies, inc., a privately held company focused on ... today announced that,Wyeth Pharmaceuticals, a division of Wyeth ... extend its evaluation of selected Raven MAb antibodies. ... payment., Under an agreement announced in January ...
... N.J., Dec. 5 Schering-Plough,Corporation (NYSE: SGP ... last,night with three top pharmaceutical industry awards: Large ... Year, and Executive of the Year for,Fred Hassan, ... are designed to recognize excellence and achievement,within the ...
Cached Biology Technology:Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies 2Schering-Plough Wins Three of Scrip's Top Pharma Industry Awards 2
(Date:9/16/2014)... 2014)The North American Menopause Society (NAMS) has published ... of midlife womenon everything from hot flashes to ... Menopause Society Recommendations for Clinical Care of Midlife ... journal Menopause . This is the first, ... of midlife women freely available to all clinicians ...
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... High school biology taught us that we inherit certain ... if you could change how these genes play out ... your diet? That,s exactly what a team of ... have proposed through their research of epigenetics research. ... by chemically modifying DNA and histone proteins, which prevent ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... 3 issue of Nature, Johns Hopkins researchers report that ... come together to turn the liver into a sugar-producing ... of sugar is a damaging problem in people with ... future drugs to fight the disease, the researchers say. ...
... Mayo Clinic researchers and conducted by the North Central Cancer ... for an incurable form of recurrent brain cancer slowed tumor ... who tried it. The same research team also developed a ... to this treatment. , Mayo researchers will present these findings ...
... by camouflage in the same way that humans are deceived, ... idea that bold contrasting colours help to break-up the body's ... as the First World War. And in biology this idea ... insects such as moths conceal themselves from predators, shaping the ...
Cached Biology News:Computational verification of protein-protein interactions by orthologous co-expression 2Computational verification of protein-protein interactions by orthologous co-expression 3'Smart drug' targets deadly brain cancer 2'Smart drug' targets deadly brain cancer 3
37-1A9...
sPLA2-XII Human, Rabbit Polyconal Antibody Anti-Human sPLA2-XII Antibody was raised in rabbits against Human sPLA2-XII His-Tagged Fusion Protein Antigen: The recombinant human protein sPLA-XII...
...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Biology Products: